Friday, July 30, 2021

Cocrystal Pharma Inc. (COCP)
CDI-45205 Shows Broad Activity Against COVID-19 Variants

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

CDI-45205 Shows Efficacy Against Delta Variant.  Cocrystal announced that its protease inhibitor against the COVID-19 virus, CDI-45205, showed potent in vitro activity against all four major variants.  These include the Delta (India or B.1.617.2), Alpha (UK or B.1.1.7), Beta (South African or B.1.351) and Gamma (Brazil or P.1). We believe these data show that the company’s technology platform for developing RNA protease inhibitors that block viral replication has broad efficacy.


Efficacy Data Provides Proof of Concept.  CDI-45205 is based on Cocrystal’s proprietary platform for developing molecules to inhibit RNA polymerases needed for viral replication.  Inhibition of these enzymes is an early step in the viral reproductive cycle that prevents replication and stops production of new viral particles. This differs from the current COVID-19 vaccines that stimulate an immune …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.